First Trust Advisors LP Sells 12,230 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

First Trust Advisors LP cut its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 8.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 134,181 shares of the company's stock after selling 12,230 shares during the period. First Trust Advisors LP owned about 0.28% of Mirum Pharmaceuticals worth $5,548,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Jones Financial Companies Lllp boosted its stake in shares of Mirum Pharmaceuticals by 100.0% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after purchasing an additional 357 shares in the last quarter. R Squared Ltd acquired a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $69,000. AlphaQuest LLC grew its holdings in Mirum Pharmaceuticals by 969.6% during the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock worth $76,000 after acquiring an additional 1,658 shares during the last quarter. Summit Investment Advisors Inc. raised its stake in shares of Mirum Pharmaceuticals by 8.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock valued at $172,000 after acquiring an additional 312 shares during the last quarter. Finally, Avanza Fonder AB acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth $189,000.

Mirum Pharmaceuticals Stock Up 0.6 %

Shares of MIRM traded up $0.27 during trading hours on Friday, hitting $43.69. The stock had a trading volume of 398,469 shares, compared to its average volume of 521,275. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.83 and a 1-year high of $54.23. The firm has a market capitalization of $2.16 billion, a P/E ratio of -21.63 and a beta of 1.00. The firm has a 50 day simple moving average of $43.23 and a 200-day simple moving average of $44.13. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $99.41 million for the quarter, compared to analyst estimates of $96.64 million. Sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Activity

In related news, COO Peter Radovich sold 2,627 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $126,673.94. Following the transaction, the chief operating officer now directly owns 26,961 shares in the company, valued at approximately $1,300,059.42. The trade was a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Peetz sold 9,102 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $438,898.44. Following the completion of the transaction, the chief executive officer now owns 115,920 shares in the company, valued at $5,589,662.40. The trade was a 7.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,557 shares of company stock worth $4,726,040 over the last three months. 22.87% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Robert W. Baird increased their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. HC Wainwright increased their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $58.20.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.